Intellia Therapeutics, Inc. NTLA
9.77 USD -0.01 (-0.10%)
Regular-session close
9.95 +0.18 +1.84%
After hours · Nov 18, 7:59 PM ET
9.66 Day range 10.49
7.95 52-week range 18.48
- YTD
- +8.68%
- 1 year
- +15.35%
News
seekingalpha.com Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE Transcript Intellia Therapeutics, Inc. ( NTLA ) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE November 12, 2026 10:00 AM EST Company Participants Jason Fredette - Vice President of…
marketbeat.com Intellia Therapeutics' One-Time HAE Therapy Cuts Attacks 87% in Trial as FDA Decision Nears Intellia Therapeutics NASDAQ: NTLA presented additional clinical data and outlined launch plans for lonvo-z, its investigational one-time gene-editing treatment for hereditary angioedema, as the…
globenewswire.com Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026 CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
globenewswire.com Intellia Therapeutics to Present at Jefferies Global Healthcare Conference in London CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
globenewswire.com Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
seekingalpha.com Intellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval Decision Intellia Therapeutics approaches a pivotal FDA decision in March 2027 for lonvo-z, potentially the first in vivo CRISPR therapy for hereditary angioedema. Lonvo-z's Phase 3 data showed ~87% attack…
zacks.com Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus NTLA's Q3 loss deepens, while progress on its lonvo-z & nex-z clinical programs & a $400 million loan facility strengthen its pipeline & financial flexibility.
zacks.com Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.92 per share a year ago.benzinga.com Intellia Therapeutics Q3 EPS $(0.91) Misses $(0.80) Estimate, Sales $7.163M Miss $10.461M Estimate Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.80) by 15.19 percent. This is a 1.09 percent increase over losses…
globenewswire.com Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and…benzinga.com Intellia Therapeutics Completed Participant Enrollment In Its MAGNITUDE-2 Study Of ATTRv-PN Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the…
globenewswire.com Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN) CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
globenewswire.com Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations Presentation at AHA on Nov. 9 to highlight cardiac outcomes following a single dose of nex-z in patients with ATTRv-PN with mixed phenotype from the Phase 1 clinical trial Presentation at ISA on Nov.…
globenewswire.com Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026 CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
globenewswire.com Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
defenseworld.net Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical Survey Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) and Neurogene (NASDAQ: NGNE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast…
zacks.com 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now BBIO, NTLA, BIIB and VKTX offer investors potential upside from promising drug pipelines and upcoming FDA decisions and pivotal study results.
globenewswire.com Intellia Therapeutics Appoints Jing L. Marantz, M.D. CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
defenseworld.net Contrasting United Therapeutics (NASDAQ:UTHR) & Intellia Therapeutics (NASDAQ:NTLA) Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) and United Therapeutics (NASDAQ: UTHR - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two…
zacks.com Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock? Intellia Therapeutics (NTLA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further…
defenseworld.net Intellia Therapeutics (NASDAQ:NTLA) Stock Picked Up by Analysts at Barclays Barclays assumed coverage on shares of Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) in a research report issued on Tuesday, MarketBeat.com reports. The brokerage set an "underweight" rating…
globenewswire.com Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing…
